May 6th 2025
De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
The Slow-Moving Antimicrobial Resistance Train is Picking-up Morbidity and Mortality Steam
December 20th 2024Resistance is expected to worsen significantly, but can a combination of both ground-level clinician stewardship actions as well as systemic reforms such as the Pasteur Act at least slow down the train?
Read More
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care Therapy
December 9th 2024A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Watch
More Bugs, No Drugs: The Growing Threat of Antibiotic Resistance
December 4th 2024Amesh A. Adalja, MD, FIDSA outlined the importance of recognizing antibiotic resistance in healthcare settings, educating patients on responsible antibiotic use, and the need for new treatments and diagnostic tools.
Watch
A Framework for Reducing Antimicrobial Stewardship Disparities
December 3rd 2024Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her work on the Equity in Antimicrobial Stewardship Efforts (EASE) framework, including progress for it, and how other institutions or providers can implement it.
Watch
With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.
Watch
Considering a Beta Lactam as Adjunctive Therapy for Staphylococcus aureus Early in Treatment
November 25th 2024This bacteremia can present heterogeneously and be difficult to contain, especially in an older patient population. Daniel B. Chastain, PharmD, BCIDP, AAHIVP, FIDSA, reviews the data of this class of therapies and how it may be clinically beneficial in combination with other antimicrobials.
Watch
Antimicrobial Resistance: Cause for Concern and Optimism?
November 22nd 2024Kenneth Lawrence, PharmD, discusses the global problem and the need for a layered, multifaceted approach to antimicrobial resistance (AMR) and some of the ongoing inroads and progress being made to address the medical issue.
Watch
One Health, One Mission: Combatting AMR During US Antibiotic Awareness Week 2024
November 22nd 2024Along with the CDC, we highlight the One Health approach and advocate for effective infection control measures, such as vaccination and innovative technologies, to prevent the spread of resistant pathogens and combat AMR.
Read More
7-Day Antibiotic Regimen Found Noninferior to 14-Day Treatment for Bloodstream Infections
November 21st 2024The BALANCE trial suggests that shorter treatment durations may reduce healthcare costs, antibiotic exposure, and antimicrobial resistance risk, providing an alternative for critically ill patients.
Read More